{
  "docId": "019de073-e8d5-735f-8ffd-8a5102406a96",
  "docSlug": "3003a94fa3be7c8f2ff0fbac5a54b26e",
  "documentTitle": "Arbutus Biopharma | Results Presentation Deck | 15 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 15,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 39,
  "notes": "The chart shows mean changes in HBsAg from baseline. The table below the chart shows patient counts (n) for each group at each time point.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-e8d5-735f-8ffd-8a5102406a96/10",
  "deckHref": "/decks/019de073-e8d5-735f-8ffd-8a5102406a96",
  "deckJsonHref": "/decks/019de073-e8d5-735f-8ffd-8a5102406a96.json",
  "deckAnchorHref": "/decks/019de073-e8d5-735f-8ffd-8a5102406a96#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Mean Changes in Virologic Parameters On-Treatment",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d82c175a-8438-4d2f-8477-b81ff40f8020",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.38,
        "x": 0.58,
        "y": 0.22
      },
      "kind": "list",
      "text": "The proportion of patients who achieved HBsAg levels <100 IU/mL and <10 IU/mL was similar in patients who received VBR+AB-729+Nrtl and AB-729+Nrtl. No patients experienced HBsAg loss or seroconversion. At the time of this analysis 0/1, 2/2 (100%), and 3/4 (75.0%) patients who received VBR+Nrtl, AB-729+Nrtl, and VBR+AB-729+Nrtl respectively, with Week 48 data met the criteria to stop all treatment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a6c842c-595f-4d14-8c49-e0fe27f8d5a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.07,
        "y": 0.78
      },
      "kind": "source-note",
      "text": "HBsAg, hepatitis B surface antigen; Nrtl, nucleos(t)ide reverse transcriptase inhibitor; SD, standard deviation; VBR, vebicorvir.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b4b2ba0-28dd-4673-aad5-99a6b8ac3cbd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Preliminary Phase 2a Triple Combination Data",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57701199-659b-430d-ba42-3db7aacc046f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}